Another Friday, another dose of bad news for Bill Ackman. Federal regulators Friday failed to approve Valeant Pharmaceuticals’ glaucoma drug due to concerns about the drug’s manufacturing facility. The news sent shares of the embattled pharma giant sliding 6.5 percent in Friday afternoon trading. Ackman’s Pershing Square has a 6 percent stake in the Canadian...
read more
Source: New York Post